News

Frequency moving to test agents with remyelination potential

Frequency Therapeutics announced that it is shifting its focus to advancing small molecules that aim to restore myelin, the protective cover around nerve fibers that is damaged and lost with multiple sclerosis (MS). This decision follows the failure of an investigative treatment for people with acquired hearing loss to…

CNM-Au8 preserves white matter in RRMS patients’ brains: Phase 2 trial

Treatment with CNM-Au8, an experimental oral liquid therapy, led to statistically significant improvements in the health of connections between brain regions for people with stable relapsing-remitting multiple sclerosis (RRMS). That’s according to new MRI data from the Phase 2 VISIONARY-MS trial (NCT03536559), which tested CNM-Au8 against a placebo in…

‘Mini-brain’ models point to poorer oligodendrocyte growth in PPMS

Using stem cells derived from people with multiple sclerosis (MS), researchers developed cerebral organoids, or “mini-brains,” to better study the cellular and molecular mechanisms leading to the neurodegenerative disorder. Initial analysis showed that patient-derived stem cells, especially those from people with primary progressive MS (PPMS), tend to be…

New remote monitoring system to be tested in MS patients in rehab

Datos Health, a remote care automation company, is collaborating with the Shirley Ryan AbilityLab, in Illinois, on a study that will gauge the effectiveness of remote therapy monitoring in patients with various conditions and disorders, including multiple sclerosis (MS). The Shirley Ryan AbilityLab, based in Chicago, provides…

Berberine, plant compound, eases disease severity in MS mouse model

Treatment with berberine, a compound found in many plants, eased disease severity and showed anti-inflammatory effects in a mouse model of multiple sclerosis (MS), a new study reports. “These results confirmed that treatment with berberine efficiently improved the disease in the animal model of MS,” the researchers wrote, noting…

Ocrevus can be safe, effective for children with active RRMS: Study

Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis (RRMS), a small study from Turkey suggests. Over about 2.5 years of the treatment, these pediatric patients experienced no relapses or MRI activity, and their disability level also improved, indicating…

Swallowing problems are common for MS patients, review study finds

Nearly half of multiple sclerosis (MS) patients experience swallowing difficulties, which is notably higher than rates seen in the general population, according to a recent review study and meta-analysis. Because swallowing problems, or dysphagia, can lead to serious, sometimes life-threatening, complications, it is important for patients to be routinely…

Mayzent, vitamin D combo alleviates MS signs in mouse study

Using Mayzent (siponimod) and vitamin D3 as a combination therapy was found to improve motor function and promote remyelination — restoring the damaged myelin sheath around nerve fibers —  in a mouse model of multiple sclerosis (MS). “Our results demonstrate for the first time the potential synergistic effects…

Sesh, MS Canada partner to help MS patients with mental health

To support the wellness journeys of Canadians living with multiple sclerosis (MS), digital healthcare company Sesh is partnering with MS Canada to provide free, unlimited access to its online mental health platform. The partnership allows patients to participate in virtual therapist-led support groups, and kickstarts research efforts…

Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial

PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in people with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

Crowdfunding Campaign Launched for MS, Other Clinical Programs

FibroBiologics has launched an online crowdfunding campaign to support the development of potential therapies in the company’s pipeline and advance its clinical programs in multiple sclerosis (MS) and other diseases. The campaign was begun in collaboration with StartEngine, an equity crowdfunding platform that facilitates investments in startup companies.

Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

MS Cognitive Problems Can Ease With Rehab, Mindfulness Training

Two alternative treatments for the cognitive challenges people with multiple sclerosis (MS) can face in daily life — cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) — were found to helpful in a clinical trial. Patients randomized to either treatment approach in the REMIND-MS study had fewer…

LAPIX, FDA Meeting Sets Way for LPX-TI641 Clinical Development

Lapix Therapeutics has met with the U.S. Food and Drug Administration (FDA) to determine how to advance its investigational treatment candidate LPX-TI641 into clinical trials for autoimmune diseases such as multiple sclerosis (MS). The pre-investigational new drug (pre-IND) meeting is usually the first formal one companies seeking to…

Relapsing MS Therapy Briumvi Now Commercially Available in US

TG Therapeutics’ Briumvi (ublituximab-xiiy), a CD20 inhibitor recently approved for adults with relapsing forms of multiple sclerosis (MS), is now commercially available in the U.S., the company announced. The treatment was approved in the U.S. late last year, with indications that include clinically isolated syndrome, relapsing-remitting MS (RRMS),…

Damian Washington video 2 thumbnail